Indian woman with dark hair, black professional attire portrait headshot

Loma Linda University Cancer Center has appointed Gayathri Nagaraj, MD, as the new Associate Director for Clinical Research, effective June 1. With an extensive background in oncology and a deep commitment to advancing patient-centered research, Nagaraj steps into this role at a pivotal time of growth and innovation for the Cancer Center.

Nagaraj said this opportunity represents both a professional milestone and a personal commitment.

“I am deeply honored to be stepping into this important role and excited to contribute to the ongoing mission of advancing cancer research and improving patient outcomes. I am eager to collaborate with our exceptional researchers, clinicians, and partners to accelerate cancer research and expand our impact across communities. As Associate Director, I will work with dedication, integrity, and a shared sense of purpose to support our strategic goals and foster an environment of innovation, inclusivity, and excellence.

I look forward to the work ahead and to contributing meaningfully to our shared vision in the fight against cancer.”

With Nagaraj’s addition, the Cancer Center’s leadership team is now composed of:

  • Mark Reeves, MD, PhD, Director, Cancer Center
  • Judy Chatigny, RN, Associate Director for Administration, Cancer Center
  • Penelope Duerksen-Hughes, PhD, Associate Director for Basic Sciences, Cancer Center
  • Gayathri Nagaraj, MD, Associate Director for Clinical Research, Cancer Center

Together, this team reflects a strong multidisciplinary approach to cancer research and care.

In her new role, Nagaraj will focus on expanding access to clinical trials and further integrating them into standard cancer care pathways at Loma Linda University Health. The goal is to ensure patients have access to emerging therapies and innovative options throughout their care journey.

Reeves said Nagaraj has wide-ranging expertise in clinical trials for cancer.

“Dr. Nagaraj’s passion for using clinical trials to incorporate cutting edge research into clinical care is a critical element as the Cancer Center moves towards NCI-designation,” he said.

The Cancer Center Clinical Trials unit is poised for major developments, including a planned move to a larger, centralized space, and the expansion will help streamline operations and foster greater collaboration between research staff and physicians.

Leaders have several areas of focus for clinical trials. One involves next-generation gene therapy trials that aim to tailor treatments based on a patient’s specific genetic makeup, which could significantly enhance treatment effectiveness and reduce side effects. Additionally, the team is preparing to launch new breast cancer trials that explore innovative targeted therapies, including those for triple-negative breast cancer, a subtype that often lacks effective treatment options. Another focus will establish trials that study the use of cellular therapies to treat cancer by modifying the immune response. This includes CAR T, TIL, and other cellular therapies. This also includes using cells to deliver gene therapies to treat a wide range of genetic diseases. A third focus will set up trials that study theranostics (molecular imaging and radionuclide therapies) to stage and treat cancer.

All of these areas of focus emphasize precision therapies that hone in on specific cancer molecules, potentially sparing damage to other normal cells.

Read more: Adult Open Studies

Read more: Pediatric Open Studies

As the Cancer Center prepares to expand its research footprint and welcome a broader patient population into trials, Nagaraj’s leadership will be instrumental in guiding strategic growth, fostering collaboration, and advancing the Cancer Center’s mission of whole-person care.

“We are committed to providing our patients with scientifically sound and cutting-edge research opportunities,” Nagaraj said. “By participating in clinical trials, individuals have the opportunity to access newer treatments that aren’t yet widely available while also contributing to the overall advancement of cancer research.”

Loma Linda University Cancer Center offers access to more open cancer trials than anywhere else in the region. The center is one of 29 in the country recognized by the National Cancer Institute as a leader in clinical trials. Learn more about the current adult and pediatric trials at the Cancer Center.